ABBV: Strong immunology growth and innovative oncology assets set the stage for long-term expansion
Immunology assets SKYRIZI and RINVOQ are driving growth with new indications and strong data, while oncology and neuroscience pipelines advance with innovative therapies and strategic capital allocation. Key milestones include phase III progress in oncology and rapid expansion in immunology.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.